Drug Profile


Alternative Names: Anti-CD3/CD19 monoclonal-antibody; CD3-CD19 DART protein; CD3xCD19 DART molecule; JNJ-64052781; MGD 011

Latest Information Update: 21 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MacroGenics
  • Developer Janssen Biotech; MacroGenics
  • Class Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma
  • Preclinical Burkitt's lymphoma

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Burkitt's lymphoma (Combination therapy) in USA (IV)
  • 07 Oct 2016 Janssen Research & Development suspends a phase I trial in Chronic lymphocytic leukaemia in USA, Australia and United Kingdom (NCT02743546)
  • 16 Sep 2016 JNJ 64052781 is now called duvortuxizumab (NCT02743546)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top